Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer

NCT01254136 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

20

Enrollment

INDUSTRY

Sponsor class

Stopped Incyte has suspended development of the compound.

Conditions

Breast Cancer

Interventions

DRUG: INCB007839 300mg BID
DRUG: Trastuzumab
DRUG: Vinorelbine

Sponsor

Incyte Corporation